111 related articles for article (PubMed ID: 34633229)
1. Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). Letter.
Kaplan-Marans E
J Urol; 2022 Jan; 207(1):242-243. PubMed ID: 34633229
[No Abstract] [Full Text] [Related]
2. Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). Reply.
Zhang KW; Guha A
J Urol; 2022 Jan; 207(1):243. PubMed ID: 34633228
[No Abstract] [Full Text] [Related]
3. Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS).
Xu R; Wang Q
J Biomed Inform; 2014 Feb; 47():171-7. PubMed ID: 24177320
[TBL] [Abstract][Full Text] [Related]
4. Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System.
Wu B; Shen P; Yin X; Yu L; Wu F; Chen C; Li J; Xu T
Br J Clin Pharmacol; 2023 Feb; 89(2):440-448. PubMed ID: 35349180
[TBL] [Abstract][Full Text] [Related]
5. Antidepressants-related cardiovascular adverse events using the adverse event reporting system.
Lee YK; Shin JS; Kim Y; Kim JH; Song YK; Oh JM; Kim IW
Psychiatry Res; 2018 Oct; 268():441-446. PubMed ID: 30130711
[TBL] [Abstract][Full Text] [Related]
6. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
[TBL] [Abstract][Full Text] [Related]
7. The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
Gorelik E; Gorelik B; Masarwa R; Perlman A; Hirsh-Raccah B; Matok I
Int J Obes (Lond); 2020 May; 44(5):1021-1027. PubMed ID: 32152496
[TBL] [Abstract][Full Text] [Related]
8. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
9. Exploring pharmacogenetic difference using adverse event database: an example of clopidogrel and cardiovascular events.
Joung KI; Kim KH; Hsieh CY; Shin JY
Pharmacogenomics; 2020 Nov; 21(16):1157-1168. PubMed ID: 33118441
[No Abstract] [Full Text] [Related]
10. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
11. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
Wittayanukorn S; Qian J; Johnson BS; Hansen RA
J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
[TBL] [Abstract][Full Text] [Related]
13. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
Shimada K; Hasegawa S; Nakao S; Mukai R; Matsumoto K; Tanaka M; Uranishi H; Masuta M; Nishida S; Shimizu S; Hayashi Y; Suzuki A; Nakamura M
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1097-1105. PubMed ID: 31502115
[TBL] [Abstract][Full Text] [Related]
14. Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.
Fang H; Su Z; Wang Y; Miller A; Liu Z; Howard PC; Tong W; Lin SM
Clin Pharmacol Ther; 2014 May; 95(5):496-8. PubMed ID: 24448476
[TBL] [Abstract][Full Text] [Related]
15. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS).
Evoy KE; Covvey JR; Peckham AM; Ochs L; Hultgren KE
Res Social Adm Pharm; 2019 Aug; 15(8):953-958. PubMed ID: 31303196
[TBL] [Abstract][Full Text] [Related]
16. Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS).
Serebruany VL; Cherepanov V; Kim MH; Litvinov O; Cabrera-Fuentes HA; Marciniak TA
Cardiology; 2017; 138(4):249-253. PubMed ID: 28898876
[TBL] [Abstract][Full Text] [Related]
17. Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization.
Huynh-Le MP; Shults RC; Connor MJ; Hattangadi-Gluth JA
Clin Genitourin Cancer; 2020 Jun; 18(3):192-200.e2. PubMed ID: 31902714
[TBL] [Abstract][Full Text] [Related]
18. Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS).
Hoffman KB; Demakas AR; Dimbil M; Tatonetti NP; Erdman CB
Drug Saf; 2014 Nov; 37(11):971-80. PubMed ID: 25255848
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS).
Zhang X; Hamadeh IS; Song S; Katz J; Moreb JS; Langaee TY; Lesko LJ; Gong Y
J Bone Miner Res; 2016 Feb; 31(2):336-40. PubMed ID: 26288087
[TBL] [Abstract][Full Text] [Related]
20. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
